Original Research
Accepted on 23 Aug 2024
REAL-LIFE EXPERIENCE WITH FIRST-LINE TREATMENT WITH DARATUMUMAB, BORTEZOMIB, MELPHALAN, AND PREDNISONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA INELIGIBLE FOR AUTOLOGOUS STEM-CELL TRANSPLANTATION
in Blood Cancer